Search
erythromycin ethyl succinate/sulfisoxazole (Eryzole, Pediazole, Sulfimycin)
200 mg erythromycin ethylsuccinate (EES) & 600 mg sulfisoxazole per 5 mL.
Indications:
1) upper & lower respiratory tract infections
2) otitis media
3) other infections in patients allergic to penicillin
Contraindications:
pregnancy-category C
safety in lactation -
Dosage:
1) adults:
-> 400 mg erythromycin/1200 mg sulfisoxazole every 6 hours
2) children: 50 mg/kg/day (based on EES dose) PO divided QID
Pharmacokinetics: elimination: kidney > liver.
Adverse effects:
1) common (> 10%)
- abdominal pain, cramping, nausea/vomiting
2) less common (1-10%)
- hypersensitivity, cholestatic jaundice, phlebitis at site of injection, oral candidiasis
3) uncommon (< 1%)
- thrombophlebitis, hypertrophic pyloric stenosis, ventricular arrhythmias, fever, rash, diarrhea, eosinophilia, headache, Stevens-Johnson syndrome, toxic epidermal necrolysis, agranulocytosis, aplastic anemia, hepatic necrosis, toxic nephrosis, crystalluria
Drug interactions:
1) Pediazole increases effects & toxicity of:
- warfarin, astemizole, terfenadine, loratadine, carbamazepine, cyclosporine, digoxin, theophylline
General
antibiotic combination
Database Correlations
PUBCHEM cid=84006
References
- The Pharmacological Basis of Therapeutics, 9th ed.
Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- Kaiser Permanente Northern California Regional Drug
Formulary, 1998
Components
erythromycin ethyl succinate (EES, Pediamycin)
sulfisoxazole (Gantrisin)